Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth

MANA INADA, AKIRA SATO, MIKA SHINDO, YOHEI YAMAMOTO, YASUHARU AKASAKI, KOICHI ICHIMURA and SEI-ICHI TANUMA
Anticancer Research December 2019, 39 (12) 6743-6750; DOI: https://doi.org/10.21873/anticanres.13889
MANA INADA
1Department of Biochemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKIRA SATO
1Department of Biochemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: akirasat@rs.tus.ac.jp
MIKA SHINDO
1Department of Biochemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan
2National Cancer Center Hospital, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOHEI YAMAMOTO
3Department of Neurosurgery, Jikei University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUHARU AKASAKI
3Department of Neurosurgery, Jikei University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOICHI ICHIMURA
4Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEI-ICHI TANUMA
1Department of Biochemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan
5Department of Genomic Medicinal Science, Research Institute for Science and Technology, Organization for Research Advancement, Tokyo University of Science, Noda, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Glioblastoma (GBM) is the most aggressive type of primary malignant brain tumour. The interaction between high-mobility group box 1 (HMGB1) and receptor for advanced glycation end-products (RAGE) is important for tumour cell growth. Previously, we identified an anticancer candidate, papaverine, that inhibited the HMGB1–RAGE interaction. Materials and Methods: Our study assessed the anticancer effects of papaverine alone or in combination with temozolomide on U87MG and T98G human GBM cells using clonogenicity assays, as well as in a U87MG xenograft mouse model. The radiosensitizing efficacy of papaverine was measured based on the clonogenicity of T98G cells. Results: Papaverine significantly inhibited the clonogenicity of U87MG and T98G cells. Compared with single treatment, the combination of papaverine and temozolomide more highly suppressed the clonogenicity of T98G cells and delayed tumour growth in the U87MG xenograft mouse model. Furthermore, papaverine increased the radiosensitivity of T98G cells. Conclusion: Papaverine is a potential anticancer drug in GBM treatment.

  • Papaverine
  • temozolomide
  • GBM
  • anti-cancer effect
  • radiosensitization
  • Received October 26, 2019.
  • Revision received November 11, 2019.
  • Accepted November 12, 2019.
  • Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
View Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 39 (12)
Anticancer Research
Vol. 39, Issue 12
December 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 13 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth
MANA INADA, AKIRA SATO, MIKA SHINDO, YOHEI YAMAMOTO, YASUHARU AKASAKI, KOICHI ICHIMURA, SEI-ICHI TANUMA
Anticancer Research Dec 2019, 39 (12) 6743-6750; DOI: 10.21873/anticanres.13889

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth
MANA INADA, AKIRA SATO, MIKA SHINDO, YOHEI YAMAMOTO, YASUHARU AKASAKI, KOICHI ICHIMURA, SEI-ICHI TANUMA
Anticancer Research Dec 2019, 39 (12) 6743-6750; DOI: 10.21873/anticanres.13889
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme
  • Google Scholar

More in this TOC Section

  • The Prognostic Significance of p16 and its Role as a Surrogate Marker for Human Papilloma Virus in Oral Squamous Cell Carcinoma: An Analysis of 281 Cases
  • Diagnostic Value of Circulating Cell-free DNA in Patients With Papillary Thyroid Cancer
  • Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer
Show more Experimental Studies

Similar Articles

Keywords

  • Papaverine
  • Temozolomide
  • GBM
  • anti-cancer effect
  • radiosensitization
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire